319 related articles for article (PubMed ID: 31672578)
1. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
[TBL] [Abstract][Full Text] [Related]
2. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
[TBL] [Abstract][Full Text] [Related]
3. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
4. Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice.
Zhou Z; Qi J; Zhao J; Lim CW; Kim JW; Kim B
J Cell Mol Med; 2020 Jan; 24(2):1383-1398. PubMed ID: 31821710
[TBL] [Abstract][Full Text] [Related]
5. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice.
Li Y; Sun JP; Wang J; Lu WH; Xie LY; Lv J; Li HX; Yang SF
Biochem Biophys Res Commun; 2019 Aug; 516(3):858-865. PubMed ID: 31266632
[TBL] [Abstract][Full Text] [Related]
6. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
7. IKKε aggravates inflammatory response via activation of NF-κB in rheumatoid arthritis.
Zhou LF; Zeng W; Sun LC; Wang Y; Jiang F; Li X; Zheng Y; Wu GM
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):2126-2133. PubMed ID: 29687872
[TBL] [Abstract][Full Text] [Related]
8. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
9. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
10. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.
Trasino SE; Tang XH; Jessurun J; Gudas LJ
J Mol Med (Berl); 2016 Oct; 94(10):1143-1151. PubMed ID: 27271256
[TBL] [Abstract][Full Text] [Related]
11. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells.
Morán-Salvador E; Titos E; Rius B; González-Périz A; García-Alonso V; López-Vicario C; Miquel R; Barak Y; Arroyo V; Clària J
J Hepatol; 2013 Nov; 59(5):1045-53. PubMed ID: 23831119
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
[TBL] [Abstract][Full Text] [Related]
14. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease.
Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM
Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
[TBL] [Abstract][Full Text] [Related]
16. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
[TBL] [Abstract][Full Text] [Related]
17. The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase Pathways.
Möller M; Wasel J; Schmetzer J; Weiß U; Meissner M; Schiffmann S; Weigert A; Möser CV; Niederberger E
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630674
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.
Dwivedi DK; Jena GB
Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):705-716. PubMed ID: 31834465
[TBL] [Abstract][Full Text] [Related]
19. Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Cruz VH; Arner EN; Wynne KW; Scherer PE; Brekken RA
Mol Metab; 2018 Oct; 16():139-149. PubMed ID: 29935921
[TBL] [Abstract][Full Text] [Related]
20. FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition.
Reilly SM; Abu-Odeh M; Ameka M; DeLuca JH; Naber MC; Dadpey B; Ebadat N; Gomez AV; Peng X; Poirier B; Walk E; Potthoff MJ; Saltiel AR
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
